Isothermal Nucleic Acid Amplification Technology Market Size, Share & Trends Analysis Report By Product, By Technology (NASBA, HDA, LAMP, SDA, SPIA, NEAR), By Application, By End Use, By Region- Global Industry Analysis, Share, Growth, Regional Outlook and Forecasts, 2022-2030

According to Nova one advisor, the global Isothermal Nucleic Acid Amplification Technology market was valued at USD 4.98 billion in 2022 and it is expected to hit around USD 11.9 billion by 2030 with a CAGR of 13.4% during the forecast period 2022 to 2030.

https://www.novaoneadvisor.com/reportimg/Isothermal-Nucleic-Acid-Amplification-Technology-Market-2022-to-2030.jpg

Key Takeaways:

  • By product, the reagents segment accounted for the largest market share in 2021 due to the widespread availability of thermo stable polymerases, and increasing demand for cost-effective diagnostic alternatives such as INAAT products
  • Loop-mediated isothermal amplification (LAMP) technology accounted for the largest share of 15.83% in 2021 as the technique allows for the use of multiple modes of detection and has the ability to detect a broad range of RNA and DNA targets
  • By application, infectious disease diagnostics held the largest share of 34.84% in 2021. This can be attributed to the rising prevalence of infectious disease, globally, and promising alternatives offered by INAAT technologies over PCR-based techniques
  • North America held a share of 42.86% and dominated the global market in 2021, due to the rapid growth in the healthcare sector and the presence of key players such as Thermo Fisher Scientific, Inc., Quidel Corporation, Meridian Bioscience, Inc., and others within the region
  • Hospitals end-use segment held the largest market share of 39.83% in 2021 due to the increasing adoption of INAAT techniques for rapid diagnostics and increasing global healthcare expenditure

A significant rise in awareness regarding the rapid testing and early detection of chronic and infectious diseases is expected to be a significant factor driving the market growth. Furthermore, the global growth in the prevalence of HIV, hepatitis, and sexually transmitted diseases, as well as the rise in adoption of INAAT for the diagnosis of such diseases, is anticipated to drive market growth.

 INAAT offers a more sensitive, accurate, and rapid alternative to traditional methods, such as culture-based identification, for the diagnosis of infectious diseases. Similarly, INAAT techniques require minimal resources and are used without the need for thermal cyclers, which significantly improves the portability of such techniques. Moreover, isothermal amplification involves the use of less expensive procedures and equipment, which can fuel its adoption in developing countries. In particular, regions such as the Asia Pacific and Africa, that have recently witnessed epidemics of infectious diseases, such as Zika virus, tuberculosis, and influenza, present significant opportunities for market expansion.

 To address the growing demand for INAAT offerings, key players are expanding their product portfolio by the launch of advanced reagents for the latest INAAT products. For instance, in March 2022, Thermo Fisher Scientific, Inc. launched its Invitrogen Super Script IV RT-LAMP Master Mix, intended for the detection of various viral pathogens. Such product launches are favoring market growth by increasing the utility of INAAT techniques for a broad range of applications.

Furthermore, COVID-19 has positively affected the market growth by increasing demand for the rapid and accurate testing alternatives used for the detection of the SARS-CoV-2 virus. Several key players have developed new INAAT-based COVID-19 testing products and have secured emergency use approvals for such products from the U.S. FDA. For instance, commercially available products in this domain include Grifols Diagnostic Solutions Inc.’s Procleix SARS-CoV-2 assay and Lucira Health, Inc.’s Lucira CHECK-IT COVID-19 test kit. Such strategic initiatives fueled by COVID-19 are likely to provide a significant stimulus to market growth in the near future.

Report Scope of the Isothermal Nucleic Acid Amplification Technology Market

Report Coverage

Details

Market Size

USD 11.9 Billion by 2030

Growth Rate

CAGR of 13.4% from 2022 to 2030

Largest Market

North America

Fastest Growing Market

Asia Pacific

Base Year

2021

Forecast Period

2022 to 2030

Segments Covered

Product, technology, application, end-use and Region,

Companies Mentioned

Alere, Inc.; bioMerieux SA; Eiken Chemical Co. Ltd; Hologic Inc.(Gen-Probe); Lucigen; Meridian Bioscience, Inc.; Ustar Biotechnologies Ltd.; QIAGEN; Quidel Corporation; Thermo Fisher Scientific, Inc; BD (Becton, Dickinson & Company); OptiGene Limited

 

Product Insights

The reagents segment dominated the market in 2021 due to the extensive usage in hospitals and primary healthcare settings, as well as the increasing availability of polymerases with high strand displacement capabilities. Furthermore, growth in the market penetration of INAAT diagnostics is expected during  the near future, adoption of the associated reagents is projected to grow at a significant rate throughout  the forecast period.

Rise in R&D interests in the development of novel diagnostics for emerging infectious diseases such as COVID-19 are driving an increasing demand for the INAAT instruments segment. Similarly, the introduction of advanced diagnostic devices, with enhanced accuracy, portability, and speed can considerably boost the market prospects for INAAT instruments used for the prevention of disease outbreaks.

Technology Insights

Loop-mediated isothermal amplification (LAMP) accounted for the largest market share of 15.83% in 2021. The technology enables multiple modes of detection such as the use of real-time fluorescence using inter calators, or lateral flow and agarose gel detection. As a result, the technique can detect a broad range of RNA and DNA targets, such as Zika virus and SARS-CoV-2 virus, in human samples. Furthermore, demand for the technique is supported by its tolerance to inhibitors that enable the use of crude samples and minimally purified nucleic acids.

HelicaseDependent Amplification (HDA) and Transcription Mediated Amplification (TMA) are other technologies that significantly contributed to the market value in 2021. Demand for these technologies is fueled by increasing scientific awareness about their potential benefits, such as the requirement of fewer steps and lesser processing time, for blood screening and diagnostic applications. High competitive rivalry between key players such as Hologic, Inc., which offers TMA products, and Quidel Corporation, which offers HDA products, is anticipated to drive steady growth for the technology segment during the forecast period.

Application Insights

INAAT applications for infectious disease diagnostics accounted for the dominant share of 34.84% in 2021. Recent introduction of specific INAAT kits and increasing incidence of HIV, hepatitis A & B, and sexually transmitted diseases are the key factors, anticipated to fuel the segment growth. Moreover, rising concerns over antimicrobial resistance and increasing focus on the prevention of epidemic outbreaks in developing countries is expected to further propel the segment growth.

Blood screening forms an important application of isothermal amplification methods due to the rising number of blood transfusions and associated blood testing requirements across the globe. Here, INAAT is widely used for the evaluation of blood quality by screening transfused blood for the presence of any infectious organisms. Furthermore, increasing research activities for the development of INAAT devices capable of detecting molecular biomarkers and multiple blood-borne pathogens are anticipated to broaden the growth prospects for the market.

End-use Insights

Hospitals held the largest market share of 39.83% in 2021. This can be attributed to the development of miniaturized point-of-care INAAT instruments that enable single-level access for hospital-based analysis. Similarly, increasing throughput and automation offered by such technologies for the processing of a large number of samples are expected to boost segment growth.

Central and reference laboratories end-use segment is expected to exhibit significant growth throughout the forecast period due to an increasing number of reference laboratories and the rising adoption of molecular diagnostic techniques in such laboratories. In addition, increasing funding from various public agencies such as the U.S. CDC and NIH is boosting the adoption of rapid analysis technologies used for the mitigation of infectious diseases.

Regional Insights

North America held the largest market share in 2021 due to the established research infrastructure and growth in demand for nucleic acid amplification-based diagnostics intended to prevent infectious diseases in the region. Furthermore, a high per capita expenditure on healthcare and increasing focus on point-of-care diagnostic methods is anticipated to drive market growth.

INAAT market for Germany held a substantial share in 2021 due to the ageing population of the country and significant focus on the healthcare systems. According to the World Bank, the country’s population over 65 years of age was estimated to account for a 21.98% share of the total population in 2021. As a result, a such high proportion of the geriatric population is expected to lead to a high prevalence of age-related disorders that can strengthen market prospects for effective INAAT devices.

Some of the prominent players in the Isothermal Nucleic Acid Amplification Technology Market include:

  • Alere, Inc.
  • bioMerieux SA
  • Eiken Chemical Co. Ltd
  • Hologic Inc.(Gen-Probe)
  • Lucigen
  • Meridian Bioscience, Inc.
  • Ustar Biotechnologies Ltd.
  • QIAGEN
  • Quidel Corporation
  • Thermo Fisher Scientific, Inc.
  • BD (Becton, Dickinson & Company)
  • OptiGene Limited

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2030. For this study, Nova one advisor, Inc. has segmented the global Isothermal Nucleic Acid Amplification Technology market

  • Product
    • Instruments
    • Reagent
  • Technology
    • NASBA
    • HDA
    • LAMP
    • SDA
    • SPIA
    • NEAR
    • TMA
    • RCA
    • RPA
    • SMAP2
    • Others
  • Application
    • Blood Screening
    • Infectious Disease Diagnostics
    • Cancer
    • Others
  • End-use
    • Hospitals
    • Central & Reference Labs
    • Others

By Geography

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East & Africa (MEA)

Key Benefits for Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the global Isothermal Nucleic Acid Amplification Technology industry analysis from 2022 to 2030 to identify the prevailing Isothermal Nucleic Acid Amplification Technology industry opportunity.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the global Isothermal Nucleic Acid Amplification Technology industry segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global Isothermal Nucleic Acid Amplification Technology industry trends, key players, market segments, application areas, and market growth strategies.

 

Report Detail

  • Report Code:7532
  • No. of Pages:150+
  • Format:PDF/PPT/Excel

Proceed To Buy

USD 3500
USD 7000